{{Infobox drug
| image = Lenacapavir.svg
| image_class = skin-invert-image
| alt =
| caption = Lenacapavir 的分子結構
| image2 = Lenacapavir 3D.png
| image_class2 = bg-transparent
| pronounce =
| tradename = Sunlenca, Yeztugo 等
| Drugs.com =
| MedlinePlus = a623005
| DailyMedID = Lenacapavir
| pregnancy_AU = B1
| pregnancy_AU_comment =
| pregnancy_category =
| routes_of_administration = 口服、皮下注射
| caption2 = Lenacapavir 分子的 3D 表示圖
| class =
| ATC_prefix = J05
| ATC_suffix = AX31
| legal_AU = S4
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA = Rx-only
| legal_CA_comment =
| legal_DE =
| legal_DE_comment =
| legal_NZ =
| legal_NZ_comment =
| legal_UK =
| legal_UK_comment =
| legal_US = Rx-only
| legal_US_comment =
| legal_EU = Rx-only
| legal_EU_comment =
| legal_UN =
| legal_UN_comment =
| legal_status =
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action =
| excretion =
| CAS_number = 2189684-44-2
| CAS_supplemental =
| PubChem =
| IUPHAR_ligand =
| DrugBank = DB15673
| ChemSpiderID = 81367881
| UNII = A9A0O6FB4H
| KEGG = D12161
| KEGG2 = D12162
| ChEBI =
| ChEMBL = 4594438
| NIAID_ChemDB =
| PDB_ligand = QNG
| synonyms = GS-CA2, GS-6207
| IUPAC_name = N-[(1S)-1-{3-[4-chloro-3-(methanesulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl]-6-[3-(methanesulfonyl)-3-methylbut-1-yn-1-yl]pyridin-2-yl}-2-(3,5-difluorophenyl)ethyl]-2-[(3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl]acetamide
| C = 39
| H = 32
| Cl = 1
| F = 10
| N = 7
| O = 5
| S = 2
| SMILES = CC(C#CC1=NC(C@@H([C@@H]4C[C@H]34)F)C(F)(F)F)=O)CC5=CC(F)=CC(F)=C5)=C(C6=CC=C(C7=C6N(CC(F)(F)F)N=C7NS(C)(=O)=O)Cl)C=C1)(S(C)(=O)=O)C
| StdInChI = 1S/C39H32ClF10N7O5S2/c1-36(2,63(3,59)60)10-9-21-5-6-22(23-7-8-26(40)30-32(23)57(17-37(43,44)45)54-35(30)55-64(4,61)62)31(51-21)27(13-18-11-19(41)14-20(42)12-18)52-28(58)16-56-34-29(33(53-56)39(48,49)50)24-15-25(24)38(34,46)47/h5-8,11-12,14,24-25,27H,13,15-17H2,1-4H3,(H,52,58)(H,54,55)/t24-,25+,27-/m0/s1
| StdInChI_comment =
| StdInChIKey = BRYXUCLEHAUSDY-WEWMWRJBSA-N
| density =
| density_notes =
| melting_point =
| melting_high =
| melting_notes =
| boiling_point =
| boiling_notes =
| solubility =
| sol_units =
| specific_rotation =
}}
利那卡韋（）是一種抗反轉錄病毒藥物，用於治療與預防人類免疫缺乏病毒／愛滋病。
利那卡韋於 2022 年 8 月取得歐盟醫療使用許可， 2022 年 11 月取得加拿大的獲准，。 它是首個獲得美國美國食品藥物管理局核准、屬於類，用於治療人類免疫缺乏病毒／愛滋病的藥物。 2025 年 6 月，利那卡韋在美國取得預防人類免疫缺乏病毒感染的醫療許可。
參考文獻
外部連結
*
*
评论 (0)